About Abiraterone Acetate API
Therapeutic CategoryAnti-Cancer/ Oncology-es
CAS Number
154229-18-2
API Technology
Steroids
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Korea DMF, Russia DMF
Mechanism of Action
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism.
Indication
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with
- Metastatic castration-resistant prostate cancer (CRPC).
- Metastatic high-risk castration-sensitive prostate cancer (CSPC)
Related APIs
Acalabrutinib
Anti-Cancer/ Oncology-es
Enzalutamide-es
Anti-Cancer/ Oncology-es
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
It belongs to Anti-neoplastic drug class
-
It is a oncology product used to treat Metastatic castration-resistant prostate cancer (CRPC). Metastatic high-risk castration-sensitive prostate cancer (CSPC)
-
Abiraterone is available in 250 mg and 500 mg dosage forms
-
We offer polymorph Form-A for Abiraterone API
-
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at api@drreddys.com.